Novian Health, the developer of Novilase breast therapy, has announced the issuance of a new US patent covering the interstitial laser therapy in combination with interstitial brachytherapy treatment.
Novian Health has developed the Novilase interstitial laser therapy (ILT) system for the ablation of small (up to 20mm) malignant breast tumors. The US patent comes as the company is conducting clinical trials of its Novilase ILT system for the breast cancer treatment.
Currently, Novian Health is enrolling patients for the clinical studies in the US, UK and France.
Previously, the company obtained 510(k) clearance from the US Food and Drug Administration for the treatment of breast fibroadenomas and currently offers Novilase at breast centers around the country that are participating in its ABLATE registry and in the Breast Cancer trial.
Novian Health president and CEO Henry Appelbaum noted the new patent covers technology that has the potential to simplify and improve therapy for breast cancer patients.
"This achievement further validates Novilase technology -- and buttresses our already strong portfolio of intellectual property covering the monitoring and control of tumor ablation," Appelbaum added.
According to Novian Health, this new technology could make the breast cancer treatment more efficient and also reduce the treatment time.
